BioSpace News Archive

The company teased data for efinopegdutide, a GLP-1/glucagon receptor co-agonist, in nonalcoholic steatohepatitis compared to Novo Nordisk’s semaglutide, which is not yet approved for NASH.

The company announced Monday with its second-quarter earnings that the regulator has officially halted the Phase I study after a child with acute myeloid leukemia died following treatment.

See inside for the top 20 biopharma companies with the most significant gaps in pay between their chief executives and median employees.

The pendulum has swung back in favor of employees, and employers are struggling to retain employees as workers become less engaged.

Jubilant Therapeutics’ differentiated, orally bioavailable molecules address both validated and novel therapeutic targets in oncology and immunology.

The biopharma company’s plan to issue and sell $100 million of shares of its common stock comes just days after releasing late-breaking Phase I/II data for menin inhibitor ziftomenib.

The biotech company is collaborating with Israel’s NeuroSense to study how the latter’s amyotrophic lateral sclerosis candidate affects plasma neurofilament levels in patients.

Eagle Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has granted Qualified Infectious Disease Product Designation under the Generating Antibiotic Incentives Now Act and Fast Track Designation for CAL02, a first-in-class non-biological bacterial virulence neutralizer, anti-infective agent being developed to treat severe community-acquired bacterial pneumonia as an add-on therapy to standard of care.

Plus Therapeutics, Inc. announced that Marc Hedrick, M.D., President and Chief Executive Officer, has been invited to participate in a fireside chat at the 2023 Healthcare Virtual Conference, presented by Maxim Group LLC and hosted by M-Vest, on Wednesday, June 21, 2023 at 3:30 p.m. ET.

Indivior PLC announced the acceptance of four abstracts for presentation at the 85th Annual Scientific Meeting of the College on Problems of Drug Dependence taking place June 17-21, 2023, in Denver, Colorado.